Pulmatrix (PULM) Competitors $6.00 +0.09 (+1.52%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends PULM vs. ANL, RVPH, ALXO, KPTI, QNCX, GNLX, PMVP, ENTX, CLSD, and IMABShould you be buying Pulmatrix stock or one of its competitors? The main competitors of Pulmatrix include Adlai Nortye (ANL), Reviva Pharmaceuticals (RVPH), ALX Oncology (ALXO), Karyopharm Therapeutics (KPTI), Quince Therapeutics (QNCX), Genelux (GNLX), PMV Pharmaceuticals (PMVP), Entera Bio (ENTX), Clearside Biomedical (CLSD), and I-Mab (IMAB). These companies are all part of the "pharmaceutical products" industry. Pulmatrix vs. Adlai Nortye Reviva Pharmaceuticals ALX Oncology Karyopharm Therapeutics Quince Therapeutics Genelux PMV Pharmaceuticals Entera Bio Clearside Biomedical I-Mab Adlai Nortye (NASDAQ:ANL) and Pulmatrix (NASDAQ:PULM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations, community ranking and valuation. Do institutionals & insiders have more ownership in ANL or PULM? 35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 11.8% of Pulmatrix shares are held by institutional investors. 0.6% of Pulmatrix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media prefer ANL or PULM? In the previous week, Adlai Nortye and Adlai Nortye both had 1 articles in the media. Adlai Nortye's average media sentiment score of 0.00 equaled Pulmatrix'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pulmatrix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation and earnings, ANL or PULM? Pulmatrix has higher revenue and earnings than Adlai Nortye. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdlai Nortye$5M15.94-$104.87MN/AN/APulmatrix$10.01M2.19-$14.12M-$2.64-2.27 Which has more volatility & risk, ANL or PULM? Adlai Nortye has a beta of -0.75, indicating that its stock price is 175% less volatile than the S&P 500. Comparatively, Pulmatrix has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500. Do analysts prefer ANL or PULM? Adlai Nortye presently has a consensus price target of $9.00, indicating a potential upside of 316.67%. Given Adlai Nortye's stronger consensus rating and higher possible upside, research analysts plainly believe Adlai Nortye is more favorable than Pulmatrix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adlai Nortye 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Pulmatrix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is ANL or PULM more profitable? Adlai Nortye has a net margin of 0.00% compared to Pulmatrix's net margin of -96.51%. Adlai Nortye's return on equity of 0.00% beat Pulmatrix's return on equity.Company Net Margins Return on Equity Return on Assets Adlai NortyeN/A N/A N/A Pulmatrix -96.51%-45.97%-30.72% Does the MarketBeat Community favor ANL or PULM? Pulmatrix received 188 more outperform votes than Adlai Nortye when rated by MarketBeat users. However, 100.00% of users gave Adlai Nortye an outperform vote while only 48.51% of users gave Pulmatrix an outperform vote. CompanyUnderperformOutperformAdlai NortyeOutperform Votes8100.00% Underperform VotesNo VotesPulmatrixOutperform Votes19648.51% Underperform Votes20851.49% SummaryAdlai Nortye beats Pulmatrix on 9 of the 14 factors compared between the two stocks. Ad Behind the MarketsWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.Take these 4 steps today to protect your retirement NOW Get Pulmatrix News Delivered to You Automatically Sign up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PULM vs. The Competition Export to ExcelMetricPulmatrixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.91M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-2.2710.5991.3417.19Price / Sales2.19195.381,117.70116.80Price / CashN/A57.1642.6437.86Price / Book1.225.104.794.78Net Income-$14.12M$151.51M$120.07M$225.60M7 Day Performance4.35%-2.15%-1.90%-1.23%1 Month Performance-1.64%-3.14%11.45%3.37%1 Year Performance198.51%11.50%30.63%16.58% Pulmatrix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PULMPulmatrix0.1934 of 5 stars$6.00+1.5%N/A+209.2%$21.91M$10.01M-2.2720Analyst ForecastNews CoverageANLAdlai Nortye1.583 of 5 stars$2.36+3.1%$9.00+281.4%-75.7%$87.08M$5M0.00127RVPHReviva Pharmaceuticals3.012 of 5 stars$2.54-2.7%$15.50+510.2%-63.5%$84.94MN/A-2.355High Trading VolumeALXOALX Oncology3.192 of 5 stars$1.60+10.3%$10.67+566.7%-87.7%$84.39MN/A-0.5440Analyst ForecastNews CoverageGap UpKPTIKaryopharm Therapeutics3.8015 of 5 stars$0.66-5.3%$5.00+654.1%-16.2%$83.67M$148.44M-0.61380QNCXQuince Therapeutics2.8954 of 5 stars$1.88-7.4%$8.50+352.1%+60.4%$82.72MN/A-1.6460Analyst ForecastAnalyst RevisionNews CoverageGNLXGenelux0.8843 of 5 stars$2.39+2.6%$18.25+663.6%-82.9%$82.55M$8,000.00-2.4510PMVPPMV Pharmaceuticals1.7944 of 5 stars$1.59+0.3%$5.80+265.9%-34.5%$82.02MN/A0.0050Positive NewsENTXEntera Bio1.4305 of 5 stars$2.21+2.3%$10.00+352.5%+195.8%$79.07M$130,000.00-8.5020CLSDClearside Biomedical2.8912 of 5 stars$1.03+1.0%$5.33+417.8%-12.8%$78.12M$8.23M-2.2930News CoverageIMABI-Mab2.5162 of 5 stars$0.95-5.1%$8.00+742.6%-38.9%$77.38M$3.27M0.0034Gap Down Related Companies and Tools Related Companies Adlai Nortye Alternatives Reviva Pharmaceuticals Alternatives ALX Oncology Alternatives Karyopharm Therapeutics Alternatives Quince Therapeutics Alternatives Genelux Alternatives PMV Pharmaceuticals Alternatives Entera Bio Alternatives Clearside Biomedical Alternatives I-Mab Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PULM) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmatrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmatrix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
